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Abstract
Background: In order to improve the health of people with Type 1 diabetes in developing
countries, a clear analysis of the constraints to insulin access and diabetes care is needed. We
developed a Rapid Assessment Protocol for Insulin Access, comprising a series of questionnaires
as well as a protocol for the gathering of other data through site visits, discussions, and document
reviews.
Methods: The Rapid Assessment Protocol for Insulin Access draws on the principles of Rapid
Assessment Protocols which have been developed and implemented in several different areas. This
protocol was adapted through a thorough literature review on diabetes, chronic condition
management and medicine supply in developing countries.
A visit to three countries in sub-Saharan Africa and meetings with different experts in the field of
diabetes helped refine the questionnaires. Following the development of the questionnaires these
were tested with various people familiar with diabetes and/or healthcare in developing countries.
The Protocol was piloted in Mozambique then refined and had two further iterations in Zambia
and Mali. Translations of questionnaires were made into local languages when necessary, with back
translation to ensure precision.
Results: In each country the protocol was implemented in 3 areas – the capital city, a large urban
centre and a predominantly rural area and their respective surroundings. Interviews were carried
out by local teams trained on how to use the tool. Data was then collected and entered into a
database for analysis.
Conclusion: The Rapid Assessment Protocol for Insulin Access was developed to provide a
situational analysis of Type 1 diabetes, in order to make recommendations to the national
Ministries of Health and Diabetes Associations. It provided valuable information on patients' access
to insulin, syringes, monitoring and care. It was thus able to sketch a picture of the health care
system with regards to its ability to care for people with diabetes. In all countries where this tool
was used the involvement of local stakeholders resulted in the process acting as a catalyst in
bringing diabetes to the attention of the health authorities.
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Background
Leonard Thompson, a Canadian child, was given his first
injection of insulin on 11 January 1922 [1]. He was the
first patient to be treated with insulin for Type 1 diabetes.
Having survived some 2 1/2 years from his diagnosis, he
had done better than most Type 1 diabetic patients in the
pre-insulin era. Three quarters of a century after its discov-
ery, insulin is still not available on an uninterrupted basis
in many parts of the developing world [2-4]. A survey in
25 countries in Africa found that in half of them insulin
was often unavailable in the large city hospitals, while in
only 5 countries was insulin regularly available in rural
areas. In some countries, insulin is not included on the
national formulary [5]. The International Diabetes Feder-
ation estimates that there are 35,100 children with Type 1
diabetes in Africa [6].
Before the discovery and purification of insulin, the aver-
age life expectancy for a patient with Type 1 diabetes was
around 12 months [7]. Some studies suggest that the
prognosis for a patient with Type 1 diabetes in sub-Saha-
ran Africa may currently be just as poor [8-10]. The rea-
sons for this are that patients with Type 1 diabetes need a
continuing supply of insulin, syringes and monitoring,
and a health care system able to provide these supplies to
all parts of the country. In parallel to these supplies diabe-
tes-trained health workers able to provide both clinical
support and patient education are also essential. There
have been no systematic studies in countries in sub-Saha-
ran Africa of health care for patients with Type 1 diabetes.
In order to study such patterns, a clear analysis of the con-
straints to insulin access and diabetes care is needed. It is
likely that increasing the supply of insulin through dona-
tions or other means is not sustainable and the root of the
problems needs to be solved. This led to the development
of the Rapid Assessment Protocol for Insulin Access
(RAPIA).
The framework of the RAPIA studies the path of insulin
from its arrival in the country to the point that it reaches
or fails to treat the patient effectively and thereby identify
how and where the system works and/or fails. The aim of
this process is to look at the provision of care for Type 1
diabetes from the viewpoint of the entire health system to
see where improvements are necessary to address the
problems that hamper access to insulin and care for their
diabetes.
Methods
The RAPIA draws on the principles of Rapid Assessment
Protocols (RAP) which have been developed and imple-
mented in different areas. The method of RAP has been
used extensively to assess services for communicable dis-
eases, including malaria, tuberculosis and STDs, for the
purpose of developing interventions. The approach cho-
sen here is to adapt existing protocols to suit the assess-
ment of access to insulin [11-13].
The main principles of the RAP are:[14]
- Pragmatism – the methods should provide adequate
information, without necessarily being 'scientifically per-
fect'. Triangulation, or cross-checking between different
sources of data is used to establish the validity and relia-
bility of the data collected.
- Speed – the methods are intended to provide relevant
information quickly, upon which decisions about health
care interventions can be made.
- Use of multiple data sources – different methods are
used to access different sources of data to get a balanced
overview.
- Cost-effectiveness – the focus is on research instruments
that provide information cheaply, and are not labour and
time intensive. Where possible, use is made of existing
data.
These were adapted through a thorough literature review
on diabetes, chronic condition management and medi-
cine supply in developing countries. This literature review
was carried out using Medline.
Based on these articles and discussions with different
experts in the field a conceptual model was developed.
This model comprised two paths, the path of insulin and
the path of care.
All the stakeholders at different levels of the health system
within a country were listed that would have an influence
on these two factors. These two paths then served as the
basis for the development of the questionnaires. Different
questionnaires targeted at different stakeholders had over-
lapping questions in order to check for internal consist-
ency.
Once the draft version of the RAPIA was ready a visit to
Mozambique, Zambia and Tanzania, with meetings at the
Ministry of Health, in hospitals, with diabetes associa-
tions, clinicians and patients enabled the lead author to
discuss the problems each person had with providing/
obtaining care and insulin. This also enabled some ques-
tions to be tested and explore the issues surrounding dia-
betes care and insulin access in more depth in the field.
The information gathered from these visits enabled the
final development of the questionnaires and protocol.
Following the development of the questionnaires theseBMC Health Services Research 2006, 6:17 http://www.biomedcentral.com/1472-6963/6/17
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were tested with various people familiar with diabetes
and/or healthcare in developing countries.
The aim of the RAPIA is to investigate the possible barriers
to insulin access that exist in a particular country. The
framework of the RAPIA studies the path of insulin from
its arrival in the country to the point that it reaches or fails
to treat the patient effectively and thereby identify how
and where the system works and/or fails. The question-
naires developed and the questions included in them tried
to follow each level of this path from the beginning with
the purchase and import of insulin to the country until
the insulin reached or failed to reach the patient. In paral-
lel the path of care was assessed from the highest levels of
the health system, to regional/provincial organisations,
hospitals, clinics and finally individual carers and
patients.
The questionnaires developed serve as a guide and can be
adapted according to the structure of the country. In order
to achieve the broad aim, the RAPIA has the following
objectives:
- To provide a range of data collection tools, from which
research teams can select those appropriate to their own
situation
- To provide suggestions of data items to collect
- To provide suggestions on data sources, data collection,
data analysis and data presentation for each of the tools
presented.
- To collect opinions and perspectives of the different peo-
ple interviewed rather than precise statistical data.
Table 1: Questionnaires that make up the RAPIA
Level Issues Addressed in each RAPIA questionnaire
MACRO
- Ministry of Health - Organisation of delivery of diabetes care
- Resources available for diabetes and insulin
- National Programs for diabetes and insulin
- Pricing of insulin
- Distribution of insulin
- Funding for insulin and diabetes
- Insulin tendering and purchase
- Ministry of Trade - Trade issues (laws, barriers to trade)
- Trade infrastructure
- Ministry of Finance - Funding of health system
- Taxes on insulin
- Funding for insulin and diabetes
- Private Sector - Pricing of insulin
- Distribution of insulin
- National Diabetes Association - Issues with diabetes and insulin
- Central Medical Store - Insulin tendering and purchase
- Insulin distribution and storage
- Insulin pricing
MESO
- Regional/District Health Organisation - Issues with diabetes and insulin
- Organisation of care for people with diabetes
- Hospitals, Clinics, Health Centres, Dispensaries, etc. - Treatment and management of people with diabetes
- Access to appropriate tools to diagnose and treat patients
- Infrastructure present and/or lacking for insulin provision
- Laboratory - Infrastructure present and/or lacking for proper diagnosis and follow-up
- Pharmacy - Insulin distribution and storage
- Insulin pricing
MICRO
- Health Workers and Traditional Healers - Problems encountered in diagnosis and treatment of patients
- Training
- Infrastructure present and/or lacking
- Tools present and/or lacking
- Patients - Diagnosis
- Access to treatment
- Cost of treatment
Taken from [10]BMC Health Services Research 2006, 6:17 http://www.biomedcentral.com/1472-6963/6/17
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Table 2: Target areas of each RAPIA questionnaire
Target questions with regards to insulin and diabetes care QUESTIONNAIRES
MACRO MESO MICRO
ABCDEFGHI JKLMNO
Funding for diabetes care and insulin X X X X X X X
Taxes and Import restrictions on insulin X X X X X X X X
Labour Resources X X X
Organisation of care X X X X X X X
Supply of insulin and related supplies (cost, mark-ups, taxes, "black 
market")
X XXXX XXXXXX X
Infrastructure X X X X X X X X X
Tools for monitoring and administration diabetes care X X X X X X X
Training X X X X X
Awareness and education X X X X X X X X
Prevalence, Incidence number of cases seen X X X X X X X X X
Process of care (from diagnosis to treatment) X X X X X X X X X
Macro – A (Ministry of Trade), B (Ministry of Finance), C (Ministry of Health), D (Private Sector), E (National Diabetes Association), F (Central 
Medical Store), G (Educators)
Meso – H (Regional Health Organisation), I (Regional Central Medical Store), J (Hospitals, Clinics, Health Centres, etc.), K (Laboratories), L 
(Pharmacies),
Micro – M (Health Workers), N (Traditional Healers), O (Patients)
The RAPIA provides a practical field guide to assist teams
in the collection, analysis and presentation of data to eval-
uate and inform the development of health care services
for diabetes management in resource poor settings. It pro-
vides the tools to enable a research team to collect infor-
mation on the structure and functioning of insulin supply
services/practices and also to conduct an assessment of
the quality of care currently provided to people with Type
1 diabetes. This information is gathered through the dif-
ferent questionnaires detailed in Table 1, site visits, docu-
ment reviews and discussions. These discussions were
usually held informally regarding a specific problem or
issue seen during an interview, site visit or document
review. They usually served the purpose of clarifying cer-
tain aspects or getting a further insight into a specific issue
in a less formal way.
The RAPIA provides information in the categories of:
- Health service structure and functioning with regards to
procurement of medicines, diabetes management
- Diabetes policies written and enacted
- Reported and observed practice for diabetes manage-
ment
- Availability of insulin, syringes and monitoring equip-
ment
- Price of insulin, syringes and monitoring equipment
- Existence of distribution networks for insulin
- Insulin supply-related knowledge and attitudes amongst
people with diabetes and their carers.
- Other problems that hamper the access to proper insulin
and care
Table 2 shows the specific areas that the different RAPIA
questionnaires target.
The RAPIA is divided into 3 components (Table 1). The
first is the Macro level which is aimed at the Ministerial
levels, Private Sector, National Diabetes Association, Cen-
tral Medical Store and Educators. Then the Meso level tar-
geted at Provincial Health Officers, "Health Care Settings"
(Hospitals, Clinics, Health Centres, etc.) and Pharmacies/
Dispensaries. Finally a Micro level where Carers (Health-
care Workers and Traditional Healers) and people with
diabetes are interviewed.
In each country the Meso and Micro levels of the protocol
were implemented in 3 areas – the capital city, a large
urban centre and a predominantly rural area and their
respective surroundings. These three areas were chosen by
local stakeholders to be representative of different geo-
graphical and socio-economic situations within the coun-BMC Health Services Research 2006, 6:17 http://www.biomedcentral.com/1472-6963/6/17
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try. Local teams trained on how to use the tool carried out
interviews.
For each of the Macro and Meso the aim was to collect all
the necessary information. This meant that sometimes
one questionnaire was answered by many people. For the
Educators 4 were chosen from both medical and nursing
faculties. In each area based on local discussions a repre-
sentative sample of healthcare centres, hospitals and pri-
vate facilities were chosen. The aim was to cover both
different geographic and socio-economic sectors of a
given area. For laboratories and pharmacies these ques-
tionnaires were carried out at each facility visited and also
in the private sector.
For the Micro level the focal point for diabetes care in the
area was interviewed as well as any healthcare worker
working with them. At each facility visited at least one per-
son was interviewed. This person was chosen based on the
fact that they would be the most likely person to treat a
person with diabetes. For traditional healers the main
areas/markets where these practictioners were present
were targeted. Local traditional experts were also identi-
fied through discussions with patients and these were also
interviewed.
With regards to patients, these were identified either
through the diabetes association or during clinic days.
Again a variety of patients were interviewed, the aim being
to reach theoretical saturation, i.e. those interviewed
reported having the same problems as the others inter-
viewed.
After the pilot of the RAPIA in Mozambique a guideline
number of interviews was established. These are detailed
in Table 3. These numbers are only to serve as a guide, the
aim being to collect as much data as possible and also to
investigate any specific problems and their reasons during
this process.
Data was then collected and entered into a database for
analysis.
Local stakeholders were identified through initial contacts
with diabetes associations and the Ministries of health in
these respective countries.
Besides the collection of data the RAPIA also identified
areas for improvement and ways of going improving the
current situation.
A copy of the RAPIA protocol is available from the lead
author.
Results
The Protocol was piloted in Mozambique and then
refined with two further iterations in Zambia and Mali.
Translations of questionnaires were made into local lan-
guages when necessary, with back translation to ensure
precision.
Mali, Mozambique and Zambia were chosen due to their
geographical, historical and socio-economic differences.
Implementing the RAPIA in these three Highly Indebted
Poor Countries (HIPCs) was to see how a sustainable
solution could be found to the issues of access to insulin
and proper diabetes care under extreme conditions of
scarce resources in the health sector.
Each interview had as its main aim to obtain the person's
perspective on the problems faced by people with diabe-
tes in the given country in gaining access to insulin and
proper diabetes care, rather than seeking precise statistical
information. Through the overlap in the areas of ques-
tioning above and by using other sources of information
(site visits, discussions and document reviews) the infor-
mation gathered can be cross-checked and triangulated
between different sources and types of information. These
different interactions also allowed for new sources of
information to be identified and used accordingly.
The RAPIA process
In each country the following steps described in Figure 1
were carried out to ensure a successful project.
Mozambique was chosen as a pilot country due to strong
local support. DB together with a team of local interview-
Table 3: Guideline number of interviews for the RAPIA
Capital City Urban Area Rural Area
Hospitals and Health Centres (Public and Private) 8 6 4
P h a r m a c i e s 864
Laboratories 8 6 4
Healthcare workers 20 10 5
Traditional Healers 8 6 4
Patients 20 10 5BMC Health Services Research 2006, 6:17 http://www.biomedcentral.com/1472-6963/6/17
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ers from the diabetes association carried out the RAPIA in
Mozambique over a period of almost 2 months. In collab-
oration with the Diabetes Association of Zambia (DAZ)
and the support of the Central Board of Health, DB carried
out the RAPIA in Zambia with a team of local interview-
ers, patients and carers from the diabetes association, over
a period of a month. Together with Santé Diabète Mali
(SDM), a local NGO, and the support of the Ministry of
Health, and the Direction Nationale de la Santé, Dr. A.
Nientao, DB carried out the RAPIA in Mali in 7 weeks. The
number of interviews carried out in the different countries
is detailed in Table 4.
Stages of the RAPIA Figure 1
Stages of the RAPIA.
Stages of the RAPIA 
Initial consultation with local stakeholders  

Designation of three areas of assessment, creation and 
training of RAPIA team, identification of interviewees 



Macro
-  Ministry of Finance 
-  Ministry of Trade 
-  Ministry of Health 
- Private  Sector 
- Diabetes  Organisation 
- Central  Store 
- Educators 


Meso 
- Regions 
- Hospitals 
- Regional  Central 
Medical Store 
- Laboratories 
- Pharmacies 
RAPIA PROCESS 


Micro
- Health  Workers 
- Traditional  Healers 
- Patients 
Analysis of Data 

In-country Report presentation 

Development of Action Plan BMC Health Services Research 2006, 6:17 http://www.biomedcentral.com/1472-6963/6/17
Page 7 of 9
(page number not for citation purposes)
Results were obtained in these three countries on the fol-
lowing:
- Estimates of prevalence for diabetes in different areas of
the country. These were calculated using patient registers,
interviews with healthcare workers and quantities of insu-
lin ordered
- Estimates of life expectancy in different areas of the
country. This was calculated using the prevalence deter-
mined above, with the incidence of 1 per 100,000 [6] used
by the International Diabetes Federation (IDF) and the
formula Prevalence = Incidence × Life Expectancy
- Purchase procedures, pricing, distribution, supply and
availability of insulin throughout the country
- Purchase procedures, pricing, distribution, supply and
availability of syringes throughout the country
- Levels of care in different facilities with regards to diabe-
tes care
- Availability and cost of diagnostics
- Levels of healthcare worker training
- Role and activities of the diabetes associations
- Policies regarding diabetes
- Role of traditional healers
- Other barriers to care and insulin, for example travel, dis-
tance and cost
This data enabled the preparation of three country specific
reports (available on http://www.access2insulin.org)
highlighting the problems identified during the RAPIA
and proposing concrete actions to address them. These
reports were presented to local stakeholders and with the
input of external experts and the IIF clear Action Plans
were developed. A more comprehensive review of the data
from Mozambique and Zambia have been published else-
where [10].
Limitations
As with any methodology certain limitations were
present. These are:
- Representativeness of the 3 areas chosen in each country
- The sample was not random as a convenience sample
was used
- Open questions used in questionnaires
- Questions with regards to its generalisability between the
different areas and different countries
- Use of different interviewers in different areas
- Many of the interviewees chosen by local partners
- Patients interviewed lucky/fortunate ones – as they are
the ones that are members of diabetes associations or have
been able to attend a facility where there is some record of
them
Out of the above list the key limitation is the non-random
selection of areas, participants and stakeholders. This is
due to the need for timely implementation and result gen-
eration and also due to the more qualitative nature of the
approach (as opposed to a quantitative survey).
Careful identification with local input is the key to mini-
mise selection bias. Triangulation is then rather the tool to
verify the information gathered, which can to some extent
also alert to non-representative (non-confirmed) findings,
as it compares data gathered through different means to
verify its validity.
Open questions are rather a strength in exploratory
research. Generalisability is limited, but the patterns
Table 4: Number of interviews and discussions for RAPIAs in Mali, Mozambique and Zambia
Type of interview/
discussion
Mali Mozambique Zambia Total
Patient 39 20 38 97
Pharmacy 20 7 25 52
Healthcare workers 24 25 60 109
Traditional Healers 20 5 19 44
Health Facilities 16 13 22 51
Regional level 11 8 4 23
Other 20 27 49 96
Total 150 105 217 472BMC Health Services Research 2006, 6:17 http://www.biomedcentral.com/1472-6963/6/17
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observed and frameworks for implementing solutions are
comparable across settings and this is again a strength of
our approach. The end product (country implementation
plan) however will be locally anchored and relevant
rather than internationally applicable.
Conclusion
Besides providing valuable information on patients'
access to insulin, syringes, monitoring and care which was
then used to help these three countries improve the care
for people with diabetes, the RAPIA was able to sketch a
picture of the health care system and its ability to treat
patients with Type 1 diabetes. In all countries where this
tool was used the involvement of local stakeholders
resulted in the process acting as a catalyst in bringing dia-
betes to the attention of the health authorities. The RAPIA
also raised the profile of diabetes associations and aware-
ness around diabetes and non-communicable diseases
(NCDs) in countries where most funding and projects are
focused on communicable diseases.
It has been proposed that illnesses such as Type 1 diabetes
may represent a 'tracer' condition for effective health care
systems [15,16], such that the management of patients
with Type 1 diabetes could act as a yardstick against which
the components of a fully functioning and effective health
care system might be judged. A system with such compo-
nents – including continuing supplies of drugs, diagnostic
facilities, health worker training and retention, and
patient education – are vital in the management of other
NCDs and of the chronic communicable diseases such as
tuberculosis and HIV/AIDS. Improvements in health care
systems are, then, a vital component of improving health
and health care across sub-Saharan Africa. Therefore the
RAPIA besides enabling health planners to assess their
health system with regards Type 1 diabetes could use this
tool for an assessment of the capacity of their health sys-
tem to deal with all chronic conditions.
It is intended that the RAPIA be freely available for use by
health system planners, in Ministries, NGOs and interna-
tional organisations, in other countries in Africa and else-
where. The latest version of the RAPIA is available from
the lead author, and discussions are proceeding with
WHO divisions in Geneva and in Africa, as well as with
the IDF, to disseminate the tool more widely for assessing
health services for diabetic patients in resource poor coun-
tries.
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